| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
87,000,000 |
| Market
Cap: |
174.87(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.4 - $10.94 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : 9.7 |
| Insider 6 Months : 10.7 |
| Insider 3/6 Months : 20.4 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Rezolute is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases related to chronic glucose imbalance. Co.'s primary clinical asset, RZ358, is a potential treatment for congenital hyperinsulinism, a pediatric genetic disorder characterized by excessive production of insulin by the pancreas. Co.'s second clinical asset, RZ402, is an oral plasma kallikrein inhibitor being developed as a potential therapy for the chronic treatment of diabetic macular edema.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
99,649 |
107,149 |
1,400,054 |
2,915,582 |
| Total Buy Value |
$203,224 |
$234,413 |
$4,446,741 |
$10,070,619 |
| Total People Bought |
3 |
4 |
7 |
7 |
| Total Buy Transactions |
5 |
7 |
15 |
39 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2025-09-18 |
2025-06-17 |
2024-12-17 |
2023-12-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Roberts Brian Kenneth |
Chief Medical Officer |
• – – |
2025-12-16 |
4 |
B |
$1.70 |
$47,600 |
D/D |
28,000 |
308,352 |
0.01 |
- |
|
| Hogenhuis Wladimir |
|
– • – |
2025-12-16 |
4 |
B |
$1.69 |
$9,549 |
D/D |
5,650 |
119,675 |
0.01 |
- |
|
| Karnawat Sunil Ratilal |
Chief Commercial Officer |
• – – |
2025-12-15 |
4 |
B |
$1.60 |
$19,599 |
D/D |
12,100 |
71,542 |
0.01 |
24% |
|
| Evans Daron |
CFO |
• – – |
2025-12-15 |
4 |
B |
$1.79 |
$8,938 |
I/I |
5,000 |
7,000 |
0.01 |
24% |
|
| Evans Daron |
CFO |
• – – |
2025-12-15 |
4 |
B |
$1.77 |
$70,640 |
D/D |
40,000 |
415,900 |
0.01 |
24% |
|
| Elam Nevan C |
CEO |
• • – |
2025-12-15 |
4 |
B |
$1.59 |
$50,880 |
D/D |
32,000 |
641,119 |
0.01 |
24% |
|
| Evans Daron |
CFO |
• • – |
2025-12-09 |
4 |
B |
$5.04 |
$53,167 |
D/D |
10,549 |
131,900 |
0.01 |
-79% |
|
| Kim Young-Jin |
|
– • – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
170,950 |
|
- |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• – – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
123,000 |
280,352 |
|
- |
|
| Karnawat Sunil Ratilal |
Chief Commercial Officer |
• – – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
32,000 |
59,442 |
|
- |
|
| Labrucherie Gil M |
|
– • – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
55,500 |
|
- |
|
| Hogenhuis Wladimir |
|
– • – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
114,025 |
|
- |
|
| Fauchet Philippe |
|
– • – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
55,500 |
|
- |
|
| Elam Nevan C |
CEO |
• • – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
317,000 |
609,119 |
|
- |
|
| Kreher Nerissa |
|
– • – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
58,576 |
|
- |
|
| Harris Erik |
|
– • – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
21,000 |
|
- |
|
| Evans Daron |
CFO |
• – – |
2025-11-19 |
4 |
A |
$0.00 |
$0 |
D/D |
107,000 |
375,900 |
|
- |
|
| Karnawat Sunil Ratilal |
Chief Commercial Officer |
• – – |
2025-08-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
9,898 |
|
-69% |
|
| Karnawat Sunil Ratilal |
Chief Commercial Officer |
• – – |
2025-08-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,442 |
|
-69% |
|
| Karnawat Sunil Ratilal |
Chief Commercial Officer |
• • – |
2025-08-18 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
27,442 |
|
- |
|
| Roberts Brian Kenneth |
Chief Medical Officer |
• • – |
2025-06-25 |
4 |
B |
$4.38 |
$10,939 |
D/D |
2,500 |
15,500 |
0.01 |
115% |
|
| Evans Daron |
CFO |
• • – |
2025-06-24 |
4 |
B |
$4.05 |
$20,250 |
D/D |
5,000 |
268,900 |
0.01 |
132% |
|
| Kreher Nerissa |
|
• • – |
2025-06-13 |
4 |
B |
$3.25 |
$9,997 |
D/D |
3,076 |
37,576 |
0.01 |
134% |
|
| Kim Young-Jin |
|
• • – |
2025-06-13 |
4 |
B |
$3.25 |
$3,999,999 |
I/I |
1,230,769 |
8,423,386 |
0.01 |
134% |
|
| Labrucherie Gil M |
|
• • – |
2025-06-10 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
34,500 |
|
- |
|
168 Records found
|
|
Page 1 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.01 (0.5%) 
